MARKET

EVLO

EVLO

Evelo Biosciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.03
+0.08
+1.62%
Closed 16:00 07/02 EDT
OPEN
5.16
PREV CLOSE
4.950
HIGH
5.36
LOW
4.920
VOLUME
294.20K
TURNOVER
--
52 WEEK HIGH
9.27
52 WEEK LOW
3.010
MARKET CAP
222.94M
P/E (TTM)
-1.8312
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EVLO stock price target is 10.33 with a high estimate of 17.00 and a low estimate of 6.00.

EPS

EVLO News

More
Evelo Biosciences to Present Clinical Data from Phase 1/2 Trial of EDP1503 at the ESMO World Congress on Gastrointestinal Cancer Virtual Meeting
GlobeNewswire · 4d ago
Evelo Biosciences to Present Clinical Data from Phase 1/2 Trial of EDP1503 at the ESMO World Congress on Gastrointestinal Cancer Virtual Meeting Jul. 1-4
CAMBRIDGE, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today
Benzinga · 5d ago
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24)
Benzinga · 06/25 12:26
Evelo Biosciences Prices 12M Share Public Offering of Common Stock @$3.75/Share
Evelo Biosciences,Inc. (NASDAQ: EVLO) announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, at a public offering price of $3.75 per share, before underwriting discounts and commissions.
Benzinga · 06/25 09:51
Evelo Bio prices stock offering at $3.75
Seeking Alpha - Article · 06/25 07:20
Evelo Biosciences Announces Proposed Public Offering of Common Stock
GlobeNewswire · 06/24 21:01
Evelo Biosciences Announces Proposed Public Offering of Common Stock; No Size Disclosed
Benzinga · 06/24 20:01
Evelo Trial Progress, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 06/24 06:18

Industry

Biotechnology & Medical Research
+0.68%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About EVLO

Evelo Biosciences, Inc. is engaged in developing therapies designed to act on gut-body network. The Company develops monoclonal microbes that are orally-delivered compositions of specific strains of naturally occurring microbes derived from a single clone. Its principal product candidates include EDP1066, EDP1815, and EDP1503 that are in the pre-clinical development stage. EDP1066 and EDP1815 are monoclonal microbial product candidates that are developed to treat inflammatory diseases that include psoriasis, atopic dermatitis, rheumatoid arthritis, and ulcerative colitis. EDP1503 is the Company's product candidate developed under oncology portfolio to treat diseases, such as colorectal cancer, renal cell carcinoma, and melanoma among others.
More

Webull offers kinds of Evelo Biosciences Inc stock information, including NASDAQ:EVLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVLO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EVLO stock methods without spending real money on the virtual paper trading platform.